REMD BIOTHERAPEUTICS, INC.
REMD-477, a fully human glucagon receptor antibody that blocks hepatic glucagon signaling to reduce glucose and ketone production in type 1 diabetes
- Sector
- Biotech
- Total capital
- $4.6M
- Federal grants
- $4.6M
- 6 awards · 2016–2021
- Rank in peer group#189 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 13
- 27 pending · first 2020
- Rank in peer group#18 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes$994K
- Federal grantHealth and Human S · Phase II · Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes$994K
- Federal grantHealth and Human S · Phase II · Assessment of Multiple Dose Administration of Glucagon Receptor Blocker REMD477 in Type 1 Diabetes$993K
- Federal grantHealth and Human S · Phase II · Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes$681K
- Federal grantHealth and Human S · Phase II · Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes$748K
- Federal grantHealth and Human S · Phase II · Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#189 · top 37%
- Granted patents#18 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 13 granted of 40- GrantedChemokine Receptor 4 (CXCR4) Antagonist AntibodiesUSPTOUS 12,617,857
- PendingC-c Chemokine Receptor Type 8 (CCR8) Antagonist AntibodiesUSPTOApplication 19117038
- GrantedAntibodies Which Bind Human Endothelin Receptor A (etar)USPTOUS 12,606,631
Show all 40 patent records
- Chemokine Receptor 4 (CXCR4) Antagonist AntibodiesMay 5, 2026 · US 12,617,857Granted
- C-c Chemokine Receptor Type 8 (CCR8) Antagonist AntibodiesApr 23, 2026 · Application 19117038Pending
- Antibodies Which Bind Human Endothelin Receptor A (etar)Apr 21, 2026 · US 12,606,631Granted
- Novel Interferon Variants And Bifunctional Fusion Molecules ThereofMay 8, 2025 · Application 18684361Pending
- Calcitonin Gene-related Peptide (cgrp) Antagonist AntibodiesApr 18, 2023 · US 11,629,184Granted
- Methods For Treating Heart Failure Using Glucagon Receptor Antagonistic AntibodiesSep 20, 2022 · US 11,446,376Granted
- Methods For Treating Type 1 Diabetes Using Glucagon Receptor Antagonistic AntibodiesSep 20, 2022 · US 11,447,555Granted
- Immunotherapy Using Antibodies That Bind Programmed Death LIGAND-1 (PD-L1)May 17, 2022 · US 11,332,531Granted
- Combination Of Glucagon Receptor Antagonists And PI3K Pathway Inhibitors For The Treatment Of CancerMay 3, 2022 · US 11,319,376Granted
- Cancer Treatment Using Antibodies That Bind Cytotoxic T-lymphocyte ANTIGEN-4 (CTLA-4)May 3, 2022 · US 11,319,372Granted
- Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic AntibodiesApr 14, 2022 · Application 17561565Pending
- Immunotherapy Using Antibodies That Bind Programmed Death 1 (PD-1)Feb 15, 2022 · US 11,248,049Granted
- ANTI-OX40 Antibodies And Methods Of Activating OX40Feb 8, 2022 · US 11,242,398Granted
- Treatment Of Autoimmune And Inflammatory Disorders Using Antibodies That Bind INTERLEUKIN-17A (IL-17A)Mar 18, 2021 · Application 17046220Pending
- Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic AntibodiesOct 29, 2020 · Application 16928441Pending
- Methods For Treating Heart Failure Using Glucagon Receptor Antagonistic AntibodiesSep 8, 2020 · US 10,765,737Granted
- Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic AntibodiesAug 25, 2020 · US 10,752,693Granted
- Methods For Treating Type 1 Diabetes Using Glucagon Receptor Antagonistic AntibodiesApr 21, 2020 · US 10,626,179Granted
- Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic AntibodiesFeb 28, 2019 · Application 15766821Pending
- Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic AntibodiesJan 3, 2019 · Application 16068218Pending
- Methods For Treating Heart Failure Using Glucagon Receptor AntagonistsMay 25, 2017 · Application 15255707Pending
- Treatment Of Autoimmune And Inflammatory Disorders Using Antibodies That Bind INTERLEUKIN-17A (IL-17A)Application PCTUS2019024794Pending
- Calcitonin Gene-related Peptide (cgrp) Antagonist AntibodiesApplication PCTUS2019019319Pending
- Combination Therapy For The Treatment Of ObesityApplication PCTUS2025016436Pending
- Cancer Treatment Using Antibodies That Bind Human CD134 (OX40) ReceptorApplication PCTUS2018044882Pending
- C-c Chemokine Receptor Type 8 (CCR8) Antagonist AntibodiesApplication PCTUS2023034246Pending
- Novel Interferon Variants And Bifunctional Fusion Molecules ThereofApplication PCTUS2022040807Pending
- Cancer Treatment Using Antibodies That Bind Cytotoxic T-lymphocyte ANTIGEN-7 (CTLA-4)Application PCTUS2018012545Pending
- Immunotherapy Using Antibodies That Bind Programmed Death 1 (PD-1)Application PCTUS2017068368Pending
- Immunotherapy Using Antibodies That Bind Programmed Death LIGAND-1 (PD-L1)Application PCTUS2017068369Pending
- Human Endothelin Receptor A (etar) Antagonist AntibodiesApplication PCTUS2021033088Pending
- Combination Of Glucagon Receptor Antagonists And PI3K Pathway Inhibitors For The Treatment Of CancerApplication PCTUS2017045390Pending
- Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic AntibodiesApplication PCTUS2017012220Pending
- Chemokine Receptor 4 (CXCR4) Antagonist AntibodiesApplication PCTUS2021028583Pending
- Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic AntibodiesApplication PCTUS2016055864Pending
- Methods For Treating Heart Failure Using Glucagon Receptor Antagonistic AntibodiesApplication PCTUS2016050183Pending
- Methods For Treating Obesity And Nonalcoholic Fatty Liver Disease Or Nonalcoholic Steatohepatitis Using Glucagon Receptor Antagonistic AntibodiesApplication PCTUS2016025336Pending
- Bifunctional Fusion Proteins For The Treatment Of ObesityApplication 63557044Pending
- Combination Therapy For The Treatment Of ObesityApplication 19617685Pending
- Combination Therapy For The Treatment Of ObesityApplication 63689992Pending
Related companies, and why
- Magenta TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Vor BiopharmaSimilar federal contract value in Biotech · null in contracts
- Sail BiomedicinesSimilar federal contract value in Biotech · null in contracts
- Tavo BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
- TEAMEDON INTERNATIONAL, INC.Similar federal contract value in Biotech · null in contracts
- Recourse Biologics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .